Scientists at the Institute of Science Tokyo developed a novel mRNA vaccine demonstrating efficacy in mitigating pathological neovascularization characteristic of age-related macular degeneration (AMD) in mouse models. This less invasive therapy could potentially replace repeated intraocular injections currently standard for AMD management. The advancement was recently published, marking a significant step toward next-generation retinal disease treatments.